Clinical Trials Logo

Covid19 clinical trials

View clinical trials related to Covid19.

Filter by:

NCT ID: NCT05198336 Completed - COVID-19 Clinical Trials

Immunogenicity of an Inactivated COVID-19 Vaccine

Start date: January 8, 2022
Phase: Phase 4
Study type: Interventional

This study is an open phase 4 clinical trial of an inactivated COVID-19 vaccine (CoronaVac) manufactured by Sinovac Research and Development Co., Ltd. The purpose of this study is to evaluate the immunogenicity of the CoronaVac in healthy children aged 3-11 years old.

NCT ID: NCT05198102 Completed - Clinical trials for Prevention of COVID-19

ZF2001 Booster Immunization Clinical Trials of 12 Months After the Completion of Basic Immunization

Start date: December 29, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the immunogenicity and safety of the recombinant novel coronavirus vaccine (CHO cells) after the booster immunization. It is planned to screen 300 subjects of 18 years old and above who have completed the basic immunization of recombinant novel coronavirus vaccine (CHO cells), to evaluate the immunogenicity and safety of the booster immunization of 12 months (window period ± 3 months) after the basic immunization. Investigate the geometric mean titer (GMT), GMI and 4 times growth rate of SARS-CoV-2 neutralizing antibody and RBD protein binding antibody 14 days, 30 days, and 6 months after booster vaccination; the incidence of all AEs within 1 month after the booster vaccination, the incidence of all serious adverse events (SAE) within 6 months after the booster vaccination.

NCT ID: NCT05198063 Completed - Clinical trials for Prevention of COVID-19

ZF2001 Booster Immunization Clinical Trials of 6 Months After the Completion of Basic Immunization

Start date: January 10, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the immunogenicity and safety of the recombinant novel coronavirus vaccine (CHO cells) after the booster immunization. It is planned to screen 300 subjects of 18 years old and above who have completed the basic immunization of recombinant novel coronavirus vaccine (CHO cells), to evaluate the immunogenicity and safety of the booster immunization of 6 months (window period ± 1 month) after the basic immunization. Investigate the geometric mean titer (GMT), GMI and 4 times growth rate of SARS-CoV-2 neutralizing antibody and RBD protein binding antibody 14 days, 30 days, and 6 months after booster vaccination; the incidence of all AEs within 1 month after the booster vaccination, the incidence of all serious adverse events (SAE) within 6 months after the booster vaccination.

NCT ID: NCT05197660 Completed - Surgery Clinical Trials

Routine Surgical Procedures During COVID-19 Pandemic: a French Nationwide Cohort Study

Start date: January 1, 2019
Phase:
Study type: Observational

Determine the consequences of COVID-19 pandemic on routine targeted surgeries. Five surgical procedures were considered : cataract surgery, hip and knee arthoplasties, coronary revascularisation by angioplasty and definitive cardiac stimulation. The objective of the study is to quantify changes of these procedures in 2020 and in 2021 (up to June) compared to 2019 taking into account their annual evolution and according to the type of operation (primary or reoperation/revision) and emergency status, if applicable.

NCT ID: NCT05197634 Completed - COVID-19 Pandemic Clinical Trials

The Impact of Covid-19 Pandemic On The Children With Autism Spectrum Disorder

Start date: September 6, 2021
Phase:
Study type: Observational

The Covid-19 outbreak has caused families and individuals to change their life routines and eating habits, and has affected their psychology, especially for children with autism, due to the change in their routines. These psychological changes may trigger the self-harming behavior that is very common in children with autism. Dental trauma, a common problem in children and adolescents, can also be seen in individuals who need special care such as autism. The aim of this study is to evaluate the susceptibility of children with autism to orofacial trauma during the pandemic period and compare them with the pre-pandemic period and the healthy group, as well as to question the lifestyle, nutritional habits, mood changes and oral health behaviors that may be related to the risk of trauma.

NCT ID: NCT05197582 Completed - COVID-19 Pandemic Clinical Trials

The Effect of Telemonitoring on Anxiety and Quality of Life in Patients in COVID 19 Quarantine

Start date: January 1, 2021
Phase: N/A
Study type: Interventional

The study was carried out to evaluate the effect of telemonitoring service to be given to patients kept under quarantine during the COVID 19 pandemic on anxiety and quality of life.

NCT ID: NCT05197569 Completed - Patient Engagement Clinical Trials

The Effect of Aromatherapy With Thyme Oil on Disease Symptoms, Vital Signs, Hemodynamic Parameters in COVID-19 Patients

Start date: January 31, 2022
Phase: N/A
Study type: Interventional

Coronavirus, which is a common infectious disease, is characterized by symptoms such as severe pain, cough, shortness of breath, dizziness, secretion, diarrhea, nausea-vomiting, weakness, runny nose, changes in sense of taste and smell, and loss of appetite. The use of thyme is common for this disease whose standard treatment is still being discussed. However, studies investigating the effectiveness of oregano oil are limited. These few studies in the literature have focused especially on the effects of thyme oil on Covid-19 symptoms. This work; It will be done to evaluate the effect of aromatherapy with thyme oil on Covid-19 symptoms, vital signs and hemodynamic parameters in Covid-19 patients. There is no study in the literature investigating the effects of all these variables.

NCT ID: NCT05197452 Completed - COVID-19 Pandemic Clinical Trials

Increasing COVID-19 Testing in Chicago's African American Testing Desserts

Start date: March 23, 2021
Phase: N/A
Study type: Interventional

This study uses a population-based approach to increase uptake of COVID-19 testing within a highly segregated and underserved African American community in Chicago.

NCT ID: NCT05197179 Completed - COVID-19 Clinical Trials

A Bridging Study of FB2001 in Healthy Subjects

Start date: December 29, 2021
Phase: Phase 1
Study type: Interventional

In the first human clinical trial conducted in the United States, single and multiple dosing of FB2001 in multiple dose groups were partially completed,and FB2001 demonstrated good safety and tolerability. The bridge study of FB2001 will be conducted in China to evaluated the safety and PK of FB2001 in healthy Chinese population. This is a randomized, double-blind, placebo-controlled study of single and multiple dosing.

NCT ID: NCT05197153 Completed - COVID-19 Vaccine Clinical Trials

A Study to Evaluate the Safety and Immunogenicity of Booster With AZD1222, mRNA-1273, or MVC-COV1901 Against COVID-19

Start date: January 22, 2022
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the safety, tolerability, and immunogenicity of booster dose of vaccine in participants who are generally healthy or with stable pre-existing health conditions. Study details include: - The study duration per participant will be approximately 209 days (28 days screening, 1 day vaccination, and 180 days follow-up). - The treatment will include 1 booster dose only. - The visit frequency will be 6 on-site visits and 1 phone visit.